ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2808

Longitudinal Assessment of Cognitive Function in SLE: Identification of Trajectories

Zahi Touma1, Jiandong Su2 and Patricia P. Katz3, 1Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, 2University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Cognitive dysfunction and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment IV: Neuropsychiatric Disease and Health Economics

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:

Cognitive function may change over time in patients with SLE, and cognitive function trajectories (CFTs) have not well been studied. This is the first study to identify CFTs in SLE and their correlates.

 

Methods:

Data were from the University of California San Francisco Lupus Outcomes Study, in which participants are followed longitudinally via annual telephone surveys. The Hopkins Verbal Learning Test-Revised (HVLT-R; measures verbal memory) was administered in years 2-7 and the Controlled Oral Word Association Test (COWAT; verbal fluency) in years 4-7, providing up to 6 and 4 years of observation, respectively. Individuals with at least 2 assessments were included in analysis.  Age- and education-stratified z-scores were derived for HVLT delayed recall and COWAT.

Proc Traj (SAS) was used to identify group-based trajectory models. One model each was fitted for the HVLT-R and COWAT. To select the best model, models with 2-5 trajectories were examined by graphic shapes, number of patients in each group, and model fitting statistics according to Baysian Information Criterion. Separate univariate/multivariable logistic regression analyses (for HVLT-R and COWAT) were then performed to look for factors at baseline associated with CFT, including sex, ethnicity, disease duration, renal problems, treatments, fatigue, depressive symptoms (CESD), and self-reported disease activity.

Results:

815 patients (92.4% female) with mean age 34.5±13.3 years at SLE diagnosis were studied. 761 and 658 individuals had at least 2 HVLT-R and COWAT scores, respectively. Two CFTs were identified for each measure (see Figure):  persistently low (29% in HVLT-R, 55% in COWAT) and persistent normal (71% in HVLT-R, 44.6% in COWAT).  In multivariable analyses, persistently normal HVLT-R was associated with Caucasian race; renal problems, intravenous glucocorticoids use in the prior year, and higher CESD scores were associated with persistently low HVLT-R (Table).  Persistently normal COWAT was associated with longer disease duration, while higher CESD score was associated with persistently low COWAT.

 

Conclusion:

Cognitive function followed particular trajectories over time in SLE, with some patients having persistently low scores while others had normal scores. Depressive symptoms were associated with persistently low function in both measures.  Other factors associated with persistently low function were measure-specific.  Additional longitudinal studies including more nuanced measures of cognitive function are needed to further explore long-term patterns of cognitive function in SLE.

 

 

 

 

 

 

 

 

 

Table. Baseline factors associated with better cognitive function trajectories in univariate and multivariate analysis

 

HVLT-R delayed recall

COWAT

 

Univariate

Multivariate

Univariate

Multivariate

Female

1.3 (0.7, 2.3)

—

1.0 (0.5, 1.8)

—

Caucasian

1.6 (1.1, 2.2)

1.5 (1.02, 2.2)

1.3 (0.9, 1.9)

—

Disease duration, year

1.0 (0.98, 1.02)

—

1.02 (1.0, 1.03)

1.02 (1.001, 1.04)

Renal problems

0.5 (0.4, 0.8)

0.6 (0.4, 0.9)

0.8 (0.5, 1.1)

—

Smoking, ever

0.8 (0.6, 1.2)

—

1.3 (0.9, 1.7)

—

Oral glucocorticoids during baseline year

0.8 (0.6, 1.1)

—

0.8 (0.6, 1.1)

—

Intravenous steroids during baseline year

0.4 (0.2, 0.8)

0.5 (0.2, 0.4)

0.9 (0.5, 1.7)

—

Plaquenil use

0.8 (0.6, 1.1)

—

1.2 (0.9, 1.7)

—

CESD score

0.96 (0.95, 0.97)

0.97 (0.96, 0.98)

0.98 (0.97, 0.99)

0.98 (0.97, 1.0)

Tabled values are odds ratios (95% confidence intervals). 

 


Disclosure: Z. Touma, None; J. Su, None; P. P. Katz, Bristol-Myers Squibb, 2.

To cite this abstract in AMA style:

Touma Z, Su J, Katz PP. Longitudinal Assessment of Cognitive Function in SLE: Identification of Trajectories [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/longitudinal-assessment-of-cognitive-function-in-sle-identification-of-trajectories/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/longitudinal-assessment-of-cognitive-function-in-sle-identification-of-trajectories/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology